Search

Your search for "vtgn" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update

June 12, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting financial results for the fiscal year ended March 31, 2024; the report also included a corporate update. Highlights of the report included that Vistagen’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call

June 7, 2024

Vistagen (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, plans to host a conference call and webcast on Tuesday, June 11, 2024, at 2 p.m. PT (5 p.m. ET). During the conference call, the company will report results for its fiscal year 2024 ended […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference

May 29, 2024

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company has announced that its management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference slated to take place in New York City on June 5 and 6, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference

May 23, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is scheduled to present two posters at this month’s American Society of Clinical Psychopharmacology Conference. The conference is scheduled for May 28–31, 2024, in Miami Beach, Florida. The posters will feature fasedienol, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference

May 7, 2024

Vistagen (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, has announced that its management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place in New York City on May 14 and 15, 2024. Vistagen’s CEO Shawn […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement

April 25, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is reporting positive results from a phase 2A pilot study of PH15, its investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. According to the data, which has […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference

April 9, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will present posters at this week’s Anxiety and Depression Association of America (“ADAA”) Conference. The three-day event is scheduled for April 11–14, 2024, in Boston. The posters will feature clinical trial data […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Continues Advancement of Fasedienol for the Acute Treatment of SAD

April 1, 2024

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days

March 11, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will be featured at the upcoming Stifel 2024 Virtual CNS Days. The two-day online event is scheduled for March 19–20, 2024. During the event, Vistagen CEO Shawn Singh will present, and company management will […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference

February 28, 2024

Vistagen (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Health Care Conference. The event is taking place from March 4 to 6, 2024, in Boston, Massachusetts. Vistagen […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update

February 14, 2024

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, is reporting its Q3 2024 financial numbers as well as providing an update on the company. Notable numbers from the report include research and development expenses reaching $4.5 million and $6.9 million for the three […]

InvestorNewsBreaks

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call

February 6, 2024

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast to report results for its fiscal year 2024 third quarter ended Dec. 31, 2023, and provide a corporate update. The call will begin at 2:00 p.m. […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain

December 27, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a notice of intention to grant a patent from the European Patent Office (“EPO”). The notice is regarding the use of AV-101, the company’s investigational […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update

November 10, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its second-quarter 2024 results for the period ended Sept. 30, 2023. Highlights of the report include that fasedienol (“PH94B”), the company’s PALISADE phase 3 program […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November

November 7, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at two scientific conferences in November: the CNS Summit 2023 and the 2023 Neuroscience Education Institute (“NEI”) Congress. According to the announcement, positive top-line […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call

November 6, 2023

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Thursday, Nov. 9, 2023, to provide a corporate […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit

October 5, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the upcoming Jefferies Biotech CNS/Neuro Summit. Held for the first time, the summit is scheduled for Oct. 11–12, 2023, in New York City. […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Pricing of $100M Underwritten Offering

October 2, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder

September 12, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on study results for PH80, one of its five investigational neuroactive nasal sprays. According to the announcement, PH80 exhibited statistically significant improvement versus placebo in […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement

September 5, 2023

Vistagen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Together with Fuji Pharma Co. (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women’s health care and acute medical care, the […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Highly Accomplished Finance Professional as CFO

August 22, 2023

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced its appointment of Cindy Anderson as chief financial officer (“CFO”), effective Aug. 21, 2023. Anderson succeeds Jerrold Dotson, whose planned retirement was announced […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2024 Financial Report, Corporate Update

August 11, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results for the first quarter of 2024, the period ending June 30, 2023; the company also released a corporate update. Highlights of the […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call

August 9, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to report its Q1 2024 financial results. In conjunction with that, the company will also host a corporate conference call. According to the announcement, […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder

August 7, 2023

Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial. The trial, to evaluate the efficacy, safety and tolerability of fasedienol (“PH94B”) nasal spray in adults diagnosed with […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)

July 17, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats. According to the update, the study demonstrated that a single intranasal administration […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment

July 14, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a Notice of Allowance from the Canadian Intellectual Property Office (“CIPO”) for a patent related to AV-101. AV-101 is the company’s oral prodrug antagonist at […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update

June 29, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is releasing its 2023 fiscal year report. Highlights of the report include positive results reported in the company’s phase 3 open label study of fasedienol (“PH94B”) in […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers

June 28, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will host a conference call and webcast today at 1:30 p.m. PT (4:30 p.m. ET). The company scheduled the event to report results for its fiscal year […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements

June 23, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced its June 22, 2023, receipt of a letter from the listing qualifications staff of the Nasdaq Stock Market LLC. The letter indicates that Vistagen has regained […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Eyes Advancement of Itruvone into Phase 2B Development

June 21, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced favorable safety and tolerability data from its U.S. phase 1 clinical trial of itruvone. “PH10” is the company’s investigational rapid-onset pherine nasal spray for the treatment […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Upcoming Maxim Group Healthcare Virtual Conference

June 16, 2023

Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will participate in this month’s Healthcare Virtual Conference presented by Maxim Group LLC. The three-day online event is scheduled for June 20–22, 2023, and will be hosted on the M-Vest platform. Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) PH80 Nasal Spray to Receive EPO Patent Approval

June 13, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received notification that the European Patent Office (“EPO”) intends to grant its patent application for PH80 nasal spray. According to the announcement, the EPO issued an […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH80 Exploratory Phase 2A Study

June 8, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that PH80, one of the company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory phase 2A study. The randomized, double-blind, […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Participate in Upcoming Jefferies Global Healthcare Conference

June 7, 2023

Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will be presenting at the 2023 Jefferies Global Healthcare Conference. Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. According to the announcement, the conference is scheduled for June 7–9, 2023, […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split

June 6, 2023

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty, as unanimously […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting

June 1, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has reported the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety disorder (“SAD”). The company […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting

May 31, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that it will be sharing the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety […]

InvestorNewsBreaks

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Recognized with MHA Platinum Bell Seal for Workplace Mental Health

May 24, 2023

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has been recognized by Mental Health America (“MHA”) for its commitment to fostering mental health and well-being in the workplace. According to the announcement, the company earned […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101

April 6, 2023

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the European Patent Office (“EPO”) has granted a patent for AV-101, Vistagen’s oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist. “Expanding our patent […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study

March 30, 2023

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting positive feedback from the U.S. Food and Drug Administration (“FDA”). The feedback is in relation to the company’s use of the Liebowitz Social Anxiety Scale […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).